LM Advisors LLC Makes New $1.51 Million Investment in Johnson & Johnson (NYSE:JNJ)

LM Advisors LLC bought a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 9,641 shares of the company’s stock, valued at approximately $1,511,000.

Several other hedge funds have also recently modified their holdings of JNJ. Keener Financial Planning LLC purchased a new position in Johnson & Johnson in the 4th quarter valued at approximately $40,000. WFA Asset Management Corp grew its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in Johnson & Johnson in the fourth quarter worth $44,000. Disciplined Equity Management Inc. purchased a new position in Johnson & Johnson in the fourth quarter worth $45,000. Finally, Altshuler Shaham Ltd grew its position in Johnson & Johnson by 37.8% in the third quarter. Altshuler Shaham Ltd now owns 317 shares of the company’s stock worth $49,000 after acquiring an additional 87 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.3 %

NYSE:JNJ traded down $0.37 during mid-day trading on Tuesday, hitting $146.76. 5,660,774 shares of the stock traded hands, compared to its average volume of 7,421,241. The stock has a market capitalization of $353.20 billion, a price-to-earnings ratio of 9.15, a PEG ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 52 week low of $143.13 and a 52 week high of $175.97. The firm’s 50 day moving average is $148.84 and its two-hundred day moving average is $154.84. The company has a quick ratio of 0.94, a current ratio of 1.17 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $0.07. The company had revenue of $21.38 billion during the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The firm’s quarterly revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.68 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were given a dividend of $1.24 per share. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, June 4th. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their price objective for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday, May 6th. Finally, Morgan Stanley decreased their price target on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $174.07.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.